Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?

Autor:	Fang P; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Noticewala SS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ludmir EB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Strati P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nair R; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nze C; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ahmed S; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Castillo LM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad L; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Westin J; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu S; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Flowers C; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Huen A; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Iyer SP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dabaja B; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jazyk:	angličtina
Zdroj:	Advances in radiation oncology [Adv Radiat Oncol] 2024 Oct 09; Vol. 9 (12), pp. 101650. Date of Electronic Publication: 2024 Oct 09 (Print Publication: 2024).
DOI:	10.1016/j.adro.2024.101650
Abstrakt:	Purpose: Extranodal NK/T-cell lymphoma (ENKTCL) is rare in the Western Hemisphere and is commonly treated with combined modality therapy (CMT). Methods and Materials: We retrospectively reviewed 35 patients treated with Ann Arbor stage I/II ENKTCL between 1994 and 2015 at a large academic cancer center in the United States. Results: With 11.6 years median follow-up, median overall survival and progression-free survival were 13.5 and 7.5 years, respectively. Eighteen (51%) patients experienced disease relapse, with 5 regional nodal relapses, of which 2 experienced combined regional and distant relapses. All 5 regional nodal relapses occurred exclusively among patients not treated with elective nodal irradiation (ENI). ENI was associated with improved progression-free survival (hazard ratio [HR], 0.21; 95% CI, 0.09-0.52; P = .018) without significant association with OS (HR, 0.33; 95% CI, 0.11-0.94; P = .11). There was a trend toward improved local control with radiation dose to the primary tumor ≥50 Gy (HR, 0.29; 95% CI, 0.08-1.08; P = .098). Conclusions: In this Western Hemisphere cohort of early-stage ENKTCL patients treated with CMT, ENI may have a potential clinical benefit, particularly in patients who are treated with non-asparaginase-containing CMT, such as in patients treated with radiation alone, patients treated with less intensive chemotherapy concurrently, or patients who are unable to tolerate intensive chemotherapy. Competing Interests: Paolo Strati is a consultant/on the advisory board for Roche-Genentech, Genmab-AbbVie, Kite-Gilead, Sobi, ADC Therapeutics, and AstraZeneca Acerta and has research support from Kite-Gilead, Sobi, ADC Therapeutics, AstraZeneca Acerta, and ALX Oncology. Loretta J. Nastoupil has received honorariums from AbbVie, AstraZeneca, BMS, Genentech, Genmab, Gilead/Kite, Incyte, Ipsen, Janssen, Merck, Novartis, Regeneron, and Takeda and has received research support from BMS, Caribou Biosciences, Genentech, Genmab, Gilead/Kite, IGM Biosciences, Ipsen, Janssen, Merck, Novartis, and Takeda. (© 2024 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu